NL-OMON50317招募中不适用
FES (16a-[18F]-fluoro-17β-estradiol)-PET: Towards a new standard for staging of clinical stage II/III and recurrent, estrogen receptor positive (ER+) breast cancer? Pilot study to compare [18F]FES-PET and [18F]FDG-PET. - FORESIGHT
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Clinical stage II/III or locoregional recurrent breast cancer (all
- •histological types) with ER+ and low grade according to Bloom Richardson
- •criteria (grade 1-2)
- •- Females aged 18 years or older at screening
- •- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2
- •- Candidates for treatment with curative intent (patients are also allowed for
- •inclusion in the current study if they have undergone recent surgery (<6 weeks)
- •for current breast cancer and require staging because of unexpected stage III
- •- [18F]FDG PET/CT imaging should be performed for staging according to standard
- •of care (in case [18F]FDG PET/CT imaging has already been performed, patients
- •can be included <=21 days after this scan)
- •- Estimated glomerular filtration rate (eGFR) >=30 ml/min
- •- Written and signed informed consent
排除标准
- •- History with another cancer within the last 5 years, except non-melanoma skin
- •- Undergoing treatment for current breast cancer such as (neo)adjuvant
- •chemotherapy, hormonal therapy (only in case of Tamoxifen), radiotherapy or
- •investigational drug therapy
- •- Pregnancy or lactating women
- •- Any medical, psychological or social condition that may interfere with the
- •subject*s safety and participation in the study, will lead to exclusion from
研究者
相似试验
进行中（未招募）
1 期
FES (16a-[18F]-fluoro-17ß-estradiol)-PET: Towards a new standard to stage clinical stage II/III and recurrent, estrogen receptor positive (ER+) breast cancer? Pilot study to compare [18F]FES-PET and [18F]FDG-PET.Breast cancer.EUCTR2018-002013-35-NLVU University Medical Center40
进行中（未招募）
1 期
FES-PET/CT: Study of a new tracer for detection of ER protein in the cell nucleus in breast cancerBreast cancerEUCTR2019-002665-35-DKMikkel Holm Vendelbo8
进行中（未招募）
不适用
Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast CancerBreast CancerNCT05088785Amsterdam UMC, location VUmc15
招募中
2 期
[18-F]-Fluordihydrotestosterone PET and [18F]-prostate specific membrane antigen in metastasized castrate resistant prostate cancermetastasized castrate resistent prostate cancer10038597Prostate cancerNL-OMON50549Vrije Universiteit Medisch Centrum36
终止
不适用
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted TherapyEstrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7NCT02149173University of Washington29